Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
(Image Credit: AdobeStock/Naypong Studio) Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline in open-angle glaucoma or ocular hypertension patients compared to the…
FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025
(Image Credit: AdobeStock/Ascannio The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of 2025. The 2 regulatory submissions include a Chemistry, Manufacturing,…
Associations between androgen exposure, PCOS, and transmasculine individuals with central serous chorioretinopathy
Danny A. Mammo, MD, a vitreoretinal surgeon and uveitis specialist at the Cole Eye Institute at Cleveland Clinic, presented research on the association between androgen exposure and central serous chorioretinopathy (CSCR) at the 2025 scientific meeting of the American Society…
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients – GlobeNewswire
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients GlobeNewswire Source: Author: | Date: 2025-08-21 05:32:00 Source: Author: | Date: 2025-08-21 05:32:00
Natural molecule discovery could help glaucoma patients – Medical Xpress
Natural molecule discovery could help glaucoma patients Medical Xpress Source: Author: | Date: 2025-08-20 18:00:00 Source: Author: | Date: 2025-08-20 18:00:00
The risk of sight-threatening diabetic retinopathy with GLP-1 RA use
Andy J. Barkmeier, MD, an associate professor of ophthalmology and vitreoretinal surgery at Mayo Clinic in Rochester, Minnesota, presented findings on GLP-1 medications and their relationship to diabetic retinopathy complications at the 2025 ASRS meeting in Long Beach, California. He…
VivaVision Biotech appoints Quan Dong Nguyen to its scientific advisory board
(Image credit: AdobeStock) VivaVision Biotech Co., Ltd., appointed Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, to its scientific advisory board. Nguyen is a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. He is also…
The emerging era of presbyopia-correcting eye drops: What’s next? – Ophthalmology Times
The emerging era of presbyopia-correcting eye drops: What’s next? Ophthalmology Times Source: Author: | Date: 2025-08-20 10:08:00 Source: Author: | Date: 2025-08-20 10:08:00
The emerging era of presbyopia-correcting eye drops: What’s next?
(Image Credit: AdobeStock/taffpixture) Since 2021, only 1 prescription eye drop for the correction of presbyopia, pilocarpine HCI ophthalmic solution 1.25% (Vuity; AbbVie), has been available, with additional options expected soon. In early 2025, a second eye drop, pilocarpine HCI ophthalmic…
Iantrek sees $42M fundraising for alternative glaucoma surgery launch – fiercebiotech.com
Iantrek sees $42M fundraising for alternative glaucoma surgery launch fiercebiotech.com Source: Author: | Date: 2025-08-20 07:00:00 Source: Author: | Date: 2025-08-20 07:00:00